TISIDB

Summary
Symbol	CD14
Name	CD14 molecule
Aliases	CD14 antigen; myeloid cell-specific leucine-rich glycoprotein; CD antigen CD14; Monocyte differentiation ant ......
Chromosomal Location	5q31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Lipid-anchor, GPI-anchor Secreted Membrane raft Golgi apparatus Note=Secreted forms may arise by cleavage of the GPI anchor.
Domain	-
Function	Coreceptor for bacterial lipopolysaccharide (PubMed:1698311, PubMed:23264655). In concert with LBP, binds to monomeric lipopolysaccharide and delivers it to the LY96/TLR4 complex, thereby mediating the innate immune response to bacterial lipopolysaccharide (LPS) (PubMed:20133493, PubMed:23264655). Acts via MyD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (PubMed:8612135). Acts as a coreceptor for TLR2:TLR6 heterodimer in response to diacylated lipopeptides and for TLR2:TLR1 heterodimer in response to triacylated lipopeptides, these clusters trigger signaling from the cell surface and subsequently are targeted to the Golgi in a lipid-raft dependent pathway (PubMed:16880211). Binds electronegative LDL (LDL(-)) and mediates the cytokine release induced by LDL(-) (PubMed:23880187).

> Gene Ontology [ TOP ]
Biological Process	GO:0001819 positive regulation of cytokine production GO:0002218 activation of innate immune response GO:0002221 pattern recognition receptor signaling pathway GO:0002224 toll-like receptor signaling pathway GO:0002237 response to molecule of bacterial origin GO:0002683 negative regulation of immune system process GO:0002755 MyD88-dependent toll-like receptor signaling pathway GO:0002756 MyD88-independent toll-like receptor signaling pathway GO:0002757 immune response-activating signal transduction GO:0002758 innate immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0006898 receptor-mediated endocytosis GO:0006909 phagocytosis GO:0007249 I-kappaB kinase/NF-kappaB signaling GO:0009266 response to temperature stimulus GO:0009306 protein secretion GO:0009408 response to heat GO:0010035 response to inorganic substance GO:0010038 response to metal ion GO:0030100 regulation of endocytosis GO:0031349 positive regulation of defense response GO:0031663 lipopolysaccharide-mediated signaling pathway GO:0032026 response to magnesium ion GO:0032479 regulation of type I interferon production GO:0032481 positive regulation of type I interferon production GO:0032493 response to bacterial lipoprotein GO:0032496 response to lipopolysaccharide GO:0032606 type I interferon production GO:0032609 interferon-gamma production GO:0032640 tumor necrosis factor production GO:0032649 regulation of interferon-gamma production GO:0032680 regulation of tumor necrosis factor production GO:0032729 positive regulation of interferon-gamma production GO:0032760 positive regulation of tumor necrosis factor production GO:0034121 regulation of toll-like receptor signaling pathway GO:0034122 negative regulation of toll-like receptor signaling pathway GO:0034127 regulation of MyD88-independent toll-like receptor signaling pathway GO:0034128 negative regulation of MyD88-independent toll-like receptor signaling pathway GO:0034142 toll-like receptor 4 signaling pathway GO:0034612 response to tumor necrosis factor GO:0035666 TRIF-dependent toll-like receptor signaling pathway GO:0038123 toll-like receptor TLR1:TLR2 signaling pathway GO:0038124 toll-like receptor TLR6:TLR2 signaling pathway GO:0045088 regulation of innate immune response GO:0045089 positive regulation of innate immune response GO:0045471 response to ethanol GO:0045807 positive regulation of endocytosis GO:0050663 cytokine secretion GO:0050707 regulation of cytokine secretion GO:0050708 regulation of protein secretion GO:0050714 positive regulation of protein secretion GO:0050715 positive regulation of cytokine secretion GO:0051047 positive regulation of secretion GO:0051222 positive regulation of protein transport GO:0051602 response to electrical stimulus GO:0060627 regulation of vesicle-mediated transport GO:0070265 necrotic cell death GO:0070266 necroptotic process GO:0070339 response to bacterial lipopeptide GO:0070391 response to lipoteichoic acid GO:0071216 cellular response to biotic stimulus GO:0071219 cellular response to molecule of bacterial origin GO:0071220 cellular response to bacterial lipoprotein GO:0071221 cellular response to bacterial lipopeptide GO:0071222 cellular response to lipopolysaccharide GO:0071223 cellular response to lipoteichoic acid GO:0071396 cellular response to lipid GO:0071706 tumor necrosis factor superfamily cytokine production GO:0071724 response to diacyl bacterial lipopeptide GO:0071725 response to triacyl bacterial lipopeptide GO:0071726 cellular response to diacyl bacterial lipopeptide GO:0071727 cellular response to triacyl bacterial lipopeptide GO:0097300 programmed necrotic cell death GO:0097305 response to alcohol GO:1903532 positive regulation of secretion by cell GO:1903555 regulation of tumor necrosis factor superfamily cytokine production GO:1903557 positive regulation of tumor necrosis factor superfamily cytokine production GO:1904951 positive regulation of establishment of protein localization
Molecular Function	GO:0001530 lipopolysaccharide binding GO:0001847 opsonin receptor activity GO:0008329 signaling pattern recognition receptor activity GO:0016019 peptidoglycan receptor activity GO:0038187 pattern recognition receptor activity GO:0070891 lipoteichoic acid binding
Cellular Component	GO:0009897 external side of plasma membrane GO:0010008 endosome membrane GO:0031225 anchored component of membrane GO:0031233 intrinsic component of external side of plasma membrane GO:0031362 anchored component of external side of plasma membrane GO:0043235 receptor complex GO:0044440 endosomal part GO:0045121 membrane raft GO:0046658 anchored component of plasma membrane GO:0046696 lipopolysaccharide receptor complex GO:0098552 side of membrane GO:0098589 membrane region GO:0098857 membrane microdomain

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04010 MAPK signaling pathway hsa04064 NF-kappa B signaling pathway hsa04145 Phagosome hsa04620 Toll-like receptor signaling pathway hsa04640 Hematopoietic cell lineage hsa04810 Regulation of actin cytoskeleton
Reactome	R-HSA-166054: Activated TLR4 signalling R-HSA-936964: Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon R-HSA-1280218: Adaptive Immune System R-HSA-1236975: Antigen processing-Cross presentation R-HSA-109581: Apoptosis R-HSA-5357769: Caspase activation via extrinsic apoptotic signalling pathway R-HSA-983169: Class I MHC mediated antigen processing & presentation R-HSA-1643685: Disease R-HSA-5602358: Diseases associated with the TLR signaling cascade R-HSA-5260271: Diseases of Immune System R-HSA-1236974: ER-Phagosome pathway R-HSA-937041: IKK complex recruitment mediated by RIP1 R-HSA-975163: IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation R-HSA-5603041: IRAK4 deficiency (TLR2/4) R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-140534: Ligand-dependent caspase activation R-HSA-5602498: MyD88 deficiency (TLR2/4) R-HSA-975155: MyD88 dependent cascade initiated on endosome R-HSA-166166: MyD88-independent TLR3/TLR4 cascade R-HSA-166058: MyD88 R-HSA-6798695: Neutrophil degranulation R-HSA-5357801: Programmed Cell Death R-HSA-5686938: Regulation of TLR by endogenous ligand R-HSA-168180: TRAF6 Mediated Induction of proinflammatory cytokines R-HSA-975138: TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation R-HSA-937072: TRAF6 mediated induction of TAK1 complex R-HSA-937061: TRIF-mediated TLR3/TLR4 signaling R-HSA-2562578: TRIF-mediated programmed cell death R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade R-HSA-168164: Toll Like Receptor 3 (TLR3) Cascade R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade R-HSA-168181: Toll Like Receptor 7/8 (TLR7/8) Cascade R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade R-HSA-168179: Toll Like Receptor TLR1 R-HSA-168188: Toll Like Receptor TLR6 R-HSA-168898: Toll-Like Receptors Cascades R-HSA-166020: Transfer of LPS from LBP carrier to CD14

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04010 MAPK signaling pathway
hsa04064 NF-kappa B signaling pathway
hsa04145 Phagosome
hsa04620 Toll-like receptor signaling pathway
hsa04640 Hematopoietic cell lineage
hsa04810 Regulation of actin cytoskeleton

Reactome

R-HSA-166054: Activated TLR4 signalling
R-HSA-936964: Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
R-HSA-1280218: Adaptive Immune System
R-HSA-1236975: Antigen processing-Cross presentation
R-HSA-109581: Apoptosis
R-HSA-5357769: Caspase activation via extrinsic apoptotic signalling pathway
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-1643685: Disease
R-HSA-5602358: Diseases associated with the TLR signaling cascade
R-HSA-5260271: Diseases of Immune System
R-HSA-1236974: ER-Phagosome pathway
R-HSA-937041: IKK complex recruitment mediated by RIP1
R-HSA-975163: IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
R-HSA-5603041: IRAK4 deficiency (TLR2/4)
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-140534: Ligand-dependent caspase activation
R-HSA-5602498: MyD88 deficiency (TLR2/4)
R-HSA-975155: MyD88 dependent cascade initiated on endosome
R-HSA-166166: MyD88-independent TLR3/TLR4 cascade
R-HSA-166058: MyD88
R-HSA-6798695: Neutrophil degranulation
R-HSA-5357801: Programmed Cell Death
R-HSA-5686938: Regulation of TLR by endogenous ligand
R-HSA-168180: TRAF6 Mediated Induction of proinflammatory cytokines
R-HSA-975138: TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
R-HSA-937072: TRAF6 mediated induction of TAK1 complex
R-HSA-937061: TRIF-mediated TLR3/TLR4 signaling
R-HSA-2562578: TRIF-mediated programmed cell death
R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade
R-HSA-168164: Toll Like Receptor 3 (TLR3) Cascade
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168181: Toll Like Receptor 7/8 (TLR7/8) Cascade
R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade
R-HSA-168179: Toll Like Receptor TLR1
R-HSA-168188: Toll Like Receptor TLR6
R-HSA-168898: Toll-Like Receptors Cascades
R-HSA-166020: Transfer of LPS from LBP carrier to CD14

Summary
Symbol	CD14
Name	CD14 molecule
Aliases	CD14 antigen; myeloid cell-specific leucine-rich glycoprotein; CD antigen CD14; Monocyte differentiation ant ......
Chromosomal Location	5q31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CD14 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between CD14 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
27325645	Melanoma	Inhibit immunity (T cell function)	Here we report the identification of a novel BDCA1(+)CD14(+) population of immunosuppressive myeloid cells that are expanded in melanoma patients and are present in dendritic cell-based vaccines, where they suppress CD4(+) T cells in an antigen-specific manner. Mechanistic investigations showed that BDCA1(+)CD14(+) cells expressed high levels of the immune checkpoint molecule PD-L1 to hinder T-cell proliferation.
25042737	B cell lymphoma	Inhibit immunity	CD14(+) HLA-DR(low/neg) immunosuppressive monocytes affect tumor growth by suppressing host antitumor immunity.
24907113	melanoma	Inhibit immunity	Suppression of NK-cell activity by PGE2-treated monocytes was compared with that of freshly isolated CD14(+)HLA-DR(low/-) monocytic MDSCs (moMDSC) from patients with melanoma.
24891322	acute myeloid leukemia	Promote immunity; increase the efficacy of immunotherapy	In these mice, CD14 was aberrantly overexpressed on granulocytes in a cell-autonomous manner, leading to a hypersensitive innate immune response to lipopolysaccharide (LPS) stimuli through CD14/Toll-like receptor 4 signaling.
29653983	squamous cell carcinoma	Inhibit immunity	To better define their T cell-independent functions within the tumor, sorted monocytic CD14+CD11b+HLA-DRlow/- MDSCs (mMDSC) from squamous cell carcinoma patients showed upregulated caspase-1 activity, which was associated with increased IL1β and IL18 expression.
18485901	Hepatocellular Carcinoma	Inhibit immunity (T cell function)	CD14(+) HLA-DR(-/low) cells were unable to stimulate an allogeneic T-cell response, suppressed autologous T-cell proliferation, and had high arginase activity, a hallmark characteristic of MDSC. Most important, CD14(+)HLA-DR(-/low) cells from HCC patients induced a CD4(+)CD25(+)Foxp3(+) regulatory T-cell population when cocultured with autologous T cells.
22955317	Non-Small Cell Lung Carcinoma	Inhibit immunity (T cell function)	Patients with NSCLC had a significantly higher ratio of CD11b(+)CD14(+) cells than healthy subjects, which was correlated with poor performance status and poor response to chemotherapy. Isolated CD11b(+)CD14(+) cells suppressed CD8(+) T-cell proliferation and IFN-γ production, and the former effect was attenuated by the inducible nitric oxide synthase (iNOS) inhibitor aminoguanidine hydrochloride, arginase inhibitor N-hydroxy-nor-l-arginine (nor-NOHA), and blocking antibodies for IL-4Rα(+) and IL-10.

Summary
Symbol	CD14
Name	CD14 molecule
Aliases	CD14 antigen; myeloid cell-specific leucine-rich glycoprotein; CD antigen CD14; Monocyte differentiation ant ......
Chromosomal Location	5q31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CD14 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CD14
Name	CD14 molecule
Aliases	CD14 antigen; myeloid cell-specific leucine-rich glycoprotein; CD antigen CD14; Monocyte differentiation ant ......
Chromosomal Location	5q31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CD14 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.158	0.716
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.531	0.863
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.115	0.959
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.134	0.825
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.325	0.87
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.717	0.779
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.044	0.936
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.396	0.814
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.436	0.826
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.418	0.855
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.872	0.807
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.243	0.175

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CD14 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	5.5	-5.5	0.572
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	6.8	-6.8	0.304
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	9.1	0	9.1	0.458
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	16.7	0	16.7	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CD14
Name	CD14 molecule
Aliases	CD14 antigen; myeloid cell-specific leucine-rich glycoprotein; CD antigen CD14; Monocyte differentiation ant ......
Chromosomal Location	5q31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD14. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CD14
Name	CD14 molecule
Aliases	CD14 antigen; myeloid cell-specific leucine-rich glycoprotein; CD antigen CD14; Monocyte differentiation ant ......
Chromosomal Location	5q31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD14. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD14. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CD14
Name	CD14 molecule
Aliases	CD14 antigen; myeloid cell-specific leucine-rich glycoprotein; CD antigen CD14; Monocyte differentiation ant ......
Chromosomal Location	5q31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD14. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CD14
Name	CD14 molecule
Aliases	CD14 antigen; myeloid cell-specific leucine-rich glycoprotein; CD antigen CD14; Monocyte differentiation ant ......
Chromosomal Location	5q31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CD14 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CD14
Name	CD14 molecule
Aliases	CD14 antigen; myeloid cell-specific leucine-rich glycoprotein; CD antigen CD14; Monocyte differentiation ant ......
Chromosomal Location	5q31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CD14 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CD14
Name	CD14 molecule
Aliases	CD14 antigen; myeloid cell-specific leucine-rich glycoprotein; CD antigen CD14; Monocyte differentiation ant ......
Chromosomal Location	5q31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CD14 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CD14